Subscribe To
Abbott's (abt) cardiomems favors heart failure management
Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patie...
March 27, 2023, 9:11 am
cardiovascular systems (csii) ails from soft volume, macro woes
Tough competition and consistent net loss continue to pose threats to cardiovascular Systems (CSII)....
March 20, 2023, 11:28 am
Esperion (espr) plummets 54% over milestone payment row
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that ...
March 17, 2023, 2:31 pm
Cvrx reiterates plans to discuss the preliminary results from the post-market phase of the beat-hf trial at tht 2023 and schedules a conference call
MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturin...
March 16, 2023, 8:30 am
Silence therapeutics: breaking the silence on an under-the-radar mid-stage sirna platform
Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmun...
March 13, 2023, 11:58 pm
Newamsterdam: an underfollowed dutch biotech cardiovascular biotech
NewAmsterdam Pharma is a Dutch SMID cap biotech focusing on cardiovascular diseases. NewAmsterdam Pharm...
March 13, 2023, 3:50 am
Esperion therapeutics (espr) down 24% in a week: here's why
Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR stu...
March 10, 2023, 12:15 pm
Fda approves respiree’s cardio-respiratory wearable
The RS001 device – developed by Singapore digital health company Respiree – measures heart rate and respiration directly and in real-time, and acc...
March 10, 2023, 8:44 am
The global stethoscope industry is forecasted for sales volume growth reaching us$ 1056 million by 2033 | future market insights, inc.
Growing Frequency of Respiratory and cardiovascular Conditions May Help Accelerate Market Growth. Steth...
March 7, 2023, 4:30 pm
cardiol therapeutics says new study results highlight the cardioprotective effects of cannabidiol
cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new study results have demonstrated the ...
March 7, 2023, 12:22 pm
Reviva pharmaceuticals to present at the 35th annual roth conference
CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clin...
March 7, 2023, 8:00 am
Stem cell therapy market size worth usd 92.08 million by 2030 at 16.20% cagr – report by market research future (mrfr)
Stem Cell Therapy Market Growth, Trends and Size Analysis by Cell Source (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord, IPSCs, and PPSCs), by Type...
March 6, 2023, 2:45 pm
Esperion therapeutics stock slumps 22% premarket as data from study of cholestrol-lowering drug fail to impress investors
The stock of Esperion Therapeutics Inc. ESPR, -0.31% slumped 22% in premarket trade Monday, as investors seemed to question whether data from a major ...
March 6, 2023, 6:52 am
Verve therapeutics: verve-101 on hold, but technology remains sound
Verve Therapeutics is a gene editing company focused on revolutionizing the treatment of cardiovascular...
March 5, 2023, 4:46 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm